Stockscreener 앱 받기
5.82
3.56%
0.20
시간 외 거래:
5.82
Acelyrin Inc 주식(SLRN)의 최신 뉴스
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
(SLRN) Proactive Strategies - Stock Traders Daily
Acelyrin, Inc. (NASDAQ:SLRN) Receives $11.17 Consensus PT from Analysts - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Short Interest Update - MarketBeat
The Manufacturers Life Insurance Company Acquires 4,163 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin (NASDAQ:SLRN) Trading Down 6.9%What's Next? - MarketBeat
(SLRN) Trading Advice - Stock Traders Daily
Acelyrin (NASDAQ:SLRN) Trading 4.8% Higher on Analyst Upgrade - MarketBeat
SLRNACELYRIN, INC. Latest Stock News & Market Updates - StockTitan
Wells Fargo & Company Boosts Acelyrin (NASDAQ:SLRN) Price Target to $15.00 - MarketBeat
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease - The Manila Times
Did Acelyrin Inc (SLRN) perform well in the last session? - US Post News
Acelyrin (NASDAQ:SLRN) Stock Price Down 2.4%Should You Sell? - MarketBeat
Acelyrin Inc (SLRN) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Acelyrin (NASDAQ:SLRN) Shares Up 5.9%Still a Buy? - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Millennium Management LLC Has $20.47 Million Stake in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Renaissance Technologies LLC Has $1.75 Million Stake in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
160,167 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Bought by Susquehanna Fundamental Investments LLC - Defense World
Susquehanna Fundamental Investments LLC Takes Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Recent Insider Activity Suggests Potential Gains for Acelyrin Inc (SLRN) - Knox Daily
Almitas Capital LLC Buys New Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Piper Sandler maintains Overweight rating on Acelyrin shares - Investing.com
Piper Sandler maintains Overweight rating on Acelyrin shares By Investing.com - Investing.com Australia
Acelyrin Inc [SLRN] Director makes an insider sale of 1 shares worth $7.0. - Knox Daily
Top investors say Acelyrin Inc (SLRN) ticks everything they need - SETE News
Acelyrin Insider Sellers Miss The Bus As Stock Jumps 12% - Simply Wall St
Can Acelyrin Inc Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Acelyrin (NASDAQ:SLRN) Shares Down 5.4% - MarketBeat
How did Acelyrin Inc (SLRN) fare last session? - US Post News
Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch (NASDAQ:SLRN) - Seeking Alpha
Acelyrin (NASDAQ:SLRN) Shares Gap Up to $4.60 - MarketBeat
Acelyrin stock spikes on upcoming presentation (NASDAQ:SLRN) - Seeking Alpha
Acelyrin announces positive results from Phase 3 trial of izokibep - TipRanks
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024 - StockTitan
Acelyrin Inc (SLRN) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Acadian Asset Management LLC Makes New $590,000 Investment in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
In the Green: Acelyrin Inc (SLRN) Closes at 4.31, Up/Down -8.30 from Previous Day - The Dwinnex
Results from Acelyrin Inc (SLRN) show risk - US Post News
SLRN’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Los Angeles Capital Management LLC Takes $693,000 Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc - Yahoo Finance
Significant Acquisition by T. Rowe Price Investment Management i - GuruFocus.com
Acelyrin announces PoC data from Phase 1/2 trial of lonigutamab - TipRanks
ACELYRIN reports positive Phase 1/2 trial data for TED therapy - Investing.com Australia
Acelyrin Inc (SLRN) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of - The Bakersfield Californian
Acelyrin, Inc. (NASDAQ:SLRN) Receives $10.83 Average Target Price from Analysts - MarketBeat
How does Acelyrin Inc (SLRN) change from a tortoise to a hare? - SETE News
Is it possible to buy Acelyrin Inc(SLRN) shares at a good price now? - US Post News
Acelyrin Inc (SLRN)’s Market Momentum: Closing Strong at 4.78, Down -0.62 - The Dwinnex
Company’s Banking Stock: Dissecting a 18.77% Quarterly Revenue Decline Amid Growth - The InvestChronicle
5.11%
0.50%
자본화:
|
볼륨(24시간):